Quote:

---

What do we think about the low mOS? Is it still a focused on regulatory endpoint?

---

The low mOS was due to those on the 350mg dose. Hard to get good results when some of the patients are on a half useless dose of medication. 350mg was why Progenics gave up and shelved leronlimab.

The mOS for the 525mg/700mg dose was 12.1+ months. Hopefully they release how long the 525mg/700mg doses mOS actually is at the conference. With one year survival for all doses at 1 year being 41.3% I would expect the mOS for 525mg/700mg to be quite a bit higher than 12.1 months. Possibly 20% higher or more.